These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17117144)

  • 1. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
    Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy.
    Berenguer J; Miralles P; Ribera JM; Rubio R; Valencia E; Mahillo B; Pintado V; Palacios R; Montes ML; Téllez MJ; La Cruz J; Torre-Cisneros J; Rodríguez-Arrondo F; Sepúlveda MA; Gutiérrez F; Peralta G; Boix V
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):422-8. PubMed ID: 18434957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
    Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
    Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
    Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
    Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
    AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
    Galicier L; Fieschi C; Borie R; Meignin V; Daniel MT; Gérard L; Oksenhendler E
    Blood; 2007 Oct; 110(8):2846-54. PubMed ID: 17609431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
    Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
    J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of AIDS-related lymphoma in South Korea.
    Kim JS; Kim SJ; Kim JS; Kim ES; Shin HJ; Chung JS; Min YH; Lee MH; Choi YJ; Bang SM; Kim JA; Cho GJ; Chi HS; Jang SS; Park CJ; Suh C; Park CW; Kim CS;
    Jpn J Clin Oncol; 2008 Feb; 38(2):134-9. PubMed ID: 18263652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.
    Gabarre J; Marcelin AG; Azar N; Choquet S; Lévy V; Lévy Y; Tubiana R; Charlotte F; Norol F; Calvez V; Spina M; Vernant JP; Autran B; Leblond V
    Haematologica; 2004 Sep; 89(9):1100-8. PubMed ID: 15377471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical features and prognosis of 100 AIDS-related lymphoma cases.
    Wu D; Chen C; Zhang M; Li Z; Wang S; Shi J; Zhang Y; Yao D; Hu S
    Sci Rep; 2019 Mar; 9(1):5381. PubMed ID: 30926889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic variables and 4-year survival outcomes in CD20 Positive AIDS-Related Lymphoma in the Anti-retroviral treatment era: A Retrospective Review from a Single Centre in KwaZulu-Natal, South Africa.
    Rapiti N; Abdelatif N; Moosa MS
    PLoS One; 2022; 17(9):e0272282. PubMed ID: 36048870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
    Barta SK; Samuel MS; Xue X; Wang D; Lee JY; Mounier N; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Little RF; Dunleavy K; Wilson WH; Wyen C; Remick SC; Kaplan LD; Ratner L; Noy A; Sparano JA
    Ann Oncol; 2015 May; 26(5):958-966. PubMed ID: 25632071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
    Crosswell HE; Bergsagel DJ; Yost R; Lew G
    Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
    Wolf T; Brodt HR; Fichtlscherer S; Mantzsch K; Hoelzer D; Helm EB; Mitrou PS; Chow KU
    Leuk Lymphoma; 2005 Feb; 46(2):207-15. PubMed ID: 15621803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.